Lucijanić, M. & Skelin, M. (2019). Platelet counts and risk of major bleeding with ibrutinib. Clinical Lymphoma Myeloma and Leukemia, 19. (7). doi: 10.1016/j.clml.2019.04.001
Lucijanić, Marko and Marko Skelin. "Platelet counts and risk of major bleeding with ibrutinib." Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 7, 2019. https://doi.org/10.1016/j.clml.2019.04.001
Lucijanić, Marko and Marko Skelin. "Platelet counts and risk of major bleeding with ibrutinib." Clinical Lymphoma Myeloma and Leukemia 19, no. 7 (2019). https://doi.org/10.1016/j.clml.2019.04.001
Lucijanić, M. and Skelin, M. (2019) 'Platelet counts and risk of major bleeding with ibrutinib', Clinical Lymphoma Myeloma and Leukemia, 19(7). doi: 10.1016/j.clml.2019.04.001
Lucijanić M, Skelin M. Platelet counts and risk of major bleeding with ibrutinib. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2019 July [cited 2024 July 20];19(7). doi: 10.1016/j.clml.2019.04.001
M. Lucijanić and M. Skelin, "Platelet counts and risk of major bleeding with ibrutinib", Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 7, July 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:295749. [Accessed: 20 July 2024]
